RxDoctor Payments Data

Steven Manley, PA

Medical · Roswell, GANPI 1699112953

Payments from drug & device makers

$5,554in general payments, 2019–2025

Across 265 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$740
  • Astellas Pharma US Inc$552
  • Pfizer$369
  • Merck$344
  • Bayer$330
  • Sumitomo Pharma America, Inc.$322
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$5,36897%
  • Education$1863%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,554 in reported general payments places this provider in the 85th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$218,921
Medicare patients
465
Services billed
13,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron53$42,657
MyrbetriqMirabegron42$34,261
Testosterone12$7,909
Tamsulosin Hcl249$3,288
Trimethoprim46$3,116
Silodosin37$2,774
Estradiol24$2,336
Potassium Citrate ErPotassium Citrate20$1,960
Solifenacin Succinate39$1,887
Desmopressin Acetate38$1,730
Fesoterodine Fumarate ErFesoterodine Fumarate19$1,575
Alfuzosin Hcl ErAlfuzosin Hcl74$1,353
Testosterone Cypionate18$1,335
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst115$1,229
Finasteride86$1,054

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$322$42,65753 claims
Astellas Pharma US IncMyrbetriq$552$34,26142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 950 medical providers in Georgia.

Other medical in Roswell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →